Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1/p66Shc-Mediated Pathway

Figure 1

Ber diminishes DOX-induced cardiac injury. Rats were treated with Ber before the administration of DOX. (a) Effects of Ber on histopathological changes in DOX-treated cardiac tissue by H&E staining (magnification, ×200). Con: normal cardiac tissue; Ber: berberine (20 mg/kg); DOX: doxorubicin (20 mg/kg); DOX+Ber 10 mg/kg, and DOX+Ber 20 mg/kg. (b) Impact of DOX and Ber on cell viability. H9c2 cells were pretreated with Ber (0.1, 1, and 10 μM) for 24 h and exposed to 1 μM DOX for 24 h; cell viability was determined by an MTT assay and is expressed as a percentage relative to the control group. (A) Dose-dependent effect of DOX on cell viability in H9c2 cells; (B) effects of Ber on the reduction in the viability rate induced by DOX in H9c2 cells. The results are presented as the (). ^△△ vs. control group, ^## vs. DOX group, and vs. Ber+DOX group.

(a)

(b)